212 related articles for article (PubMed ID: 21568936)
1. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.
Mudra DR; Desino KE; Desai PV
Curr Drug Metab; 2011 Oct; 12(8):750-73. PubMed ID: 21568936
[TBL] [Abstract][Full Text] [Related]
2. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
3. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
4. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
6. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
7. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
Suzuki K; Taniyama K; Aoyama T; Watanabe Y
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
[TBL] [Abstract][Full Text] [Related]
9. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
Ito K; Kusuhara H; Sugiyama Y
Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
[TBL] [Abstract][Full Text] [Related]
10. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.
Pan X; Yamazaki S; Neuhoff S; Zhang M; Pilla Reddy V
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1485-1496. PubMed ID: 34729944
[TBL] [Abstract][Full Text] [Related]
11. Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
Wang E; Lew K; Barecki M; Casciano CN; Clement RP; Johnson WW
Chem Res Toxicol; 2001 Dec; 14(12):1596-603. PubMed ID: 11743742
[TBL] [Abstract][Full Text] [Related]
12. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.
Li M; de Graaf IA; van de Steeg E; de Jager MH; Groothuis GM
Toxicol In Vitro; 2017 Apr; 40():26-33. PubMed ID: 27939799
[TBL] [Abstract][Full Text] [Related]
13. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.
Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH
J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658
[TBL] [Abstract][Full Text] [Related]
14. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
15. Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin.
Choi JS; Piao YJ; Kang KW
Arch Pharm Res; 2011 Apr; 34(4):607-13. PubMed ID: 21544726
[TBL] [Abstract][Full Text] [Related]
16. Modulation of expression/function of intestinal P-glycoprotein under disease states.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):59-78. PubMed ID: 31821048
[No Abstract] [Full Text] [Related]
17. A study of intestinal absorption of bicyclol in rats: active efflux transport and metabolism as causes of its poor bioavailability.
Tan W; Chen H; Zhao J; Hu J; Li Y
J Pharm Pharm Sci; 2008; 11(3):97-105. PubMed ID: 18801310
[TBL] [Abstract][Full Text] [Related]
18. Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.
Tachibana T; Kato M; Takano J; Sugiyama Y
Curr Drug Metab; 2010 Nov; 11(9):762-77. PubMed ID: 21189139
[TBL] [Abstract][Full Text] [Related]
19. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and P-glycoprotein inhibition by myricetin.
Choi SJ; Shin SC; Choi JS
Arch Pharm Res; 2011 Feb; 34(2):309-15. PubMed ID: 21380815
[TBL] [Abstract][Full Text] [Related]
20. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]